Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma
ConclusionsFurther detailed elucidation of fibroblast growth factor receptor 2 fusion status is expected to contribute to the development of promising therapeutic options for patients suffering from recurrent or unresectable intrahepatic cholangiocarcinoma.
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Bile Duct Cancer | Cancer | Cancer & Oncology | Chemotherapy | Cholangiocarcinoma | Cytology | Genetics | Japan Health | Study